Prospects and Challenges into the Role of Gut Microbiome in Health and Disease

Impact of microbiome-based interventions on gastrointestinal pathogen colonization in the intensive care unit

Alexa Choy and Daniel E. Freedberg

Abstract: In the intensive care unit (ICU), colonization of the gastrointestinal tract by potentially pathogenic bacteria is common and often precedes clinical infection. Though effective in the short term, traditional antibiotic-based decolonization methods may contribute to rising resistance in the long term. Novel therapies instead focus on restoring gut microbiome equilibrium to achieve pathogen colonization resistance. This review summarizes the existing data regarding microbiome-based approaches to gastrointestinal pathogen colonization in ICU patients with a focus on prebiotics, probiotics, and synbiotics.

Keywords: Gut microbiome, microbiome-based intervention, intensive care unit, gastrointestinal colonization, probiotics, prebiotics, synbiotics

Introduction
In the intensive care unit (ICU), colonization of the gastrointestinal tract by potentially pathogenic bacteria is common and often precedes clinical infection. Though effective in the short term, traditional antibiotic-based decolonization methods may contribute to rising resistance in the long term. Novel therapies instead focus on restoring gut microbiome equilibrium to achieve pathogen colonization resistance. The purpose of this review is to summarize the existing data regarding microbiome-based approaches to gastrointestinal pathogen colonization in ICU patients with a focus on prebiotics, probiotics, and synbiotics.

Gastrointestinal pathogen colonization during critical illness

Routes of pathogen colonization in the ICU
Admission to the ICU is associated with a dramatic loss of phylogenetic diversity in the gastrointestinal microbiome. This change in gut microbial composition allows pathogenic organisms, such as Clostridium difficile (more recently reclassified as Clostridioides difficile), Pseudomonas aeruginosa, Candida species, vancomycin-resistant enterococci (VRE), and other multidrug resistant organisms (MDRO) to proliferate within and colonize the gut. Critical illness itself can facilitate gastrointestinal pathogen colonization. Sepsis, one of the most common conditions in the ICU, is characterized by a dysregulated host response to infection that appears to alter gut microbial composition for the worse. Sepsis disrupts gut integrity via endogenous catecholamine production, gut hypoperfusion, degradation of the intestinal mucus layer, and decreased bile salt production. This in turn disrupts the intestinal microenvironment, allowing pathogenic organisms to dominate and existing bacteria to become more virulent.

Many of the interventions in the ICU also impact susceptibility to enteric colonization. Broad-spectrum antibiotics are used in 70% of medical ICU patients and are an important risk factor for pathogen colonization. Antibiotic exposure depletes the microbiome of many endogenous species leaving the gut highly vulnerable to colonization by antibiotic-resistant pathogens. Antibiotics can also facilitate the proliferation of resistant bacteria already present in the gut by
eliminating antibiotic-sensitive competitors within the same species. This increases the relative abundance of antibiotic-resistant bacteria in the gut and ultimately leads to increased dissemination of these strains into the ICU environment. Transmission of resistant bacteria between patients can then occur via contact with healthcare workers, adjacent patients, or contaminated objects. Antibiotics therefore impact colonization pressure at the ward level, increasing colonization and infection risk in patients who do not themselves receive antibiotics. Other common ICU interventions, such as proton pump inhibitors, immunosuppressive agents, and enteral feeding (or lack of feeding) also alter the gut microbiome and influence colonization of the digestive tract.

**Implications of gastrointestinal pathogen colonization**

Around 4–11% of all patients in the ICU have guts that are colonized with methicillin-resistant *Staphylococcus aureus* (MRSA), VRE, or MDR Gram-negative bacteria at the time of ICU admission, among patients who are free of MDROs on admission, an additional 12–14% become colonized during their ICU stay. Gastrointestinal colonization with MDROs increases risk for subsequent clinical infection with the colonizing organisms as much as 10-fold. Subsequent mortality rates are high with MDR infection causing up to 9 deaths for every 100 patients admitted to the ICU.

Colonization by *Candida* species is also very common and can occur in up to 80% of critically ill patients after 1 week in the ICU. Common species include *C. albicans*, *C. glabrata*, *C. parapsilosis*, *C. krusei*, and *C. tropicalis*. Colonization is a well-established risk factor for subsequent *Candida* infection, leading to the development of the *Candida* colonization index as an early warning tool for invasive candidiasis. Although the proportion of colonized ICU patients who later develop invasive candidiasis is low, associated mortality from invasive infection ranges from 5% to 71%.

Gastrointestinal colonization can also increase risk for extra-intestinal infections. When patients shed gastrointestinal bacteria into the ICU environment via feces, subsequent inoculation back into the patient via contaminated intravenous or urinary catheter insertion can occur. Other more direct routes of infection can also occur, such as aspiration of gastric contents or bacterial translocation across edematous bowel. While it is unknown how frequently such events happen, an increasingly large number of studies support the idea that most new healthcare-associated infections do not come from other patients but instead from colonizing bacteria present within the patient’s own gut at the time of hospital admission.

Interventions aimed at the prevention or eradication of gastrointestinal pathogens therefore have the potential to prevent clinical infection.

**Traditional approach to pathogen colonization**

Selective digestive decontamination (SDD) has shown effectiveness for gut decolonization since the 1980s. SDD relies on prophylactic administration of oropharyngeal and enteral antimicrobials throughout the ICU stay coupled with a parenteral antibiotic within 4 days of ICU admission. SDD antibiotics ideally target potential pathogens such as aerobic Gram-negative rods, *Staphylococcus aureus*, and yeasts while trying to minimize perturbation to endogenous, anaerobic flora. High-quality randomized trials show that SDD is effective in reducing ICU-acquired infections by pathogenic gut colonizers and may even provide mortality benefit, though some major studies have been negative. Long-term studies have shown reduction in the unit-level use of antibiotics, underlining the potential benefit of SDD in ICU settings.

Despite relatively strong supporting evidence, SDD has faced concern that the selective pressure of antibiotics will lead to the emergence of new resistance. Rebound increases in resistant pathogens after SDD have been demonstrated in a handful of studies, yet there is surprisingly little evidence that SDD leads to long-term MDRO colonization and infection, as one might fear it would. A 21-year longitudinal study on the long-term ecological effects of SDD found no significant increase in the incidence rates of resistant microbes at the ICU level despite an overall increase in antimicrobial resistance at the hospital level. This study was conducted in a region with low rates of resistance, and SDD trials have been centered at a few large European institutions making their results less generalizable.
the most candid assessment of SDD is that clinicians are reluctant to use antibiotics to combat a fundamentally antibiotic-related problem.

**Pre-, pro-, and synbiotics for pathogen colonization**

Given the lack of widespread adoption of SDD, alternative approaches to gastrointestinal colonization are needed for the ICU. Supplementation with probiotics, in tandem with or separately from a prebiotic, has been hypothesized as a safe, cost-effective approach to colonization resistance. We review in detail the current evidence regarding the impact of prebiotics, probiotics, and synbiotics on gastrointestinal colonization and clinical outcomes in ICU patients.

**Prebiotics**

Prebiotics are non-digestible dietary components, such as oligosaccharides, fiber, and inulin, that selectively promote the proliferation of commensal gut microbiota. In theory, prebiotic supplementation could enhance the growth and protective effects of beneficial endogenous flora in critically ill patients and confer a transitive benefit to the host through colonization resistance. This benefit could be because the modified flora directly competes with and crowds out pathogens, or because prebiotic fiber is metabolized into short-chain fatty acids (SCFAs) which have direct benefits, or from other mechanisms. There is also evidence in animal models that prebiotics can have microbiome-independent effects that modulate the host inflammatory response directly. A recent study found that exposure to prebiotics alters the response to pathogen-induced kinase activation in intestinal epithelial cells and dampens the inflammatory response to lipopolysaccharide in vivo without altering gut microbiota.

Other studies have shown that non-digestible oligosaccharides influence B-cell responses and macrophage markers in mice with and without a microbiome.

A handful of studies have investigated prebiotics in the ICU. O’Keefe et al. examined the short-term clinical tolerance and fecal SCFA concentrations in response to progressive fiber supplementation in 13 ICU patients. After fiber supplementation, there was a dramatic increase in Firmicutes and other SCFA producers and an increase in their metabolites, acetate, propionate, and butyrate. Our own retrospective study of 129 ICU patients demonstrated a similar increase in SCFA producers with higher amounts of fiber. These findings, assuming SCFAs are indeed beneficial, support the value of fiber and other prebiotics in maintaining gut microbial homeostasis. However, other trials, including a study of oligofructose/inulin in ICU patients receiving enteral nutrition, have shown no impact on the microbiome.

There is also no compelling evidence that prebiotics can impact clinical outcomes. A prospective, single-blind randomized trial with 237 ICU patients investigated the impact of a high-protein formula enriched with arginine, fiber, and antioxidants on the rates of ICU-associated infection, length of stay, and mortality. While no significant differences in mortality were observed, the incidence of catheter-related sepsis was significantly lower in the intervention group (0.4 episodes/1000 ICU days versus control 5.5 episodes/1000 ICU days). Another study (30 patients) comparing early enteral nutrition with prebiotic fiber supplementation in ICU patients with severe pancreatitis versus standard enteral feeds found a reduction in hospital length of stay (10 days versus 15 days) and lower rates of complications, including multiorgan failure, sepsis, and death.

The impact of prebiotics on gastrointestinal pathogen colonization has been examined in a small number of studies in non-ICU patients. A recent study profiled the microbiome of 87 children treated with azithromycin with or without lactulose. Patients in the azithromycin-only group had a statistically significant increase in the relative abundance of pathogenic bacteria such as *Streptococcus* that was not demonstrated in the prebiotic supplementation group. The prebiotic group also had higher fecal concentrations of protective *Lactobacillus* species.

As these studies suggest, prebiotic trials have been heterogeneous both in terms of the interventions tested and in terms of trial outcomes. Overall, data supporting prebiotics for gastrointestinal pathogen colonization in ICU patients are sparse.

**Probiotics**

Probiotics are live, ingestible microorganisms that can confer health benefits on to their host.
mechanisms by which these symbionts may deter pathogen colonization include competition, reduction of gut pH, enhancement of innate and adaptive immunity, and production of antimicrobial substances. Several systematic reviews and meta-analyses have evaluated the benefits of probiotics in critically ill patients. Probiotic administration has been associated with several favorable infection-related outcomes, including reduced incidence of overall infections, and in ICU-acquired ventilator-associated pneumonia.

At least 5 randomized-controlled studies with 48–208 patients have investigated the effects of *Lactobacillus*-based probiotics on gut colonization in adult ICU patients. The first study investigated the impact of a probiotic drink containing $5 \times 10^7$ colony-forming units (CFU) per ml of *Lactobacillus plantarum*, on gastric colonization via nasogastric aspirate at days 1, 4, and 8 of ICU admission. The study enrolled 103 patients and also investigated intestinal permeability, endotoxin exposure, inflammatory marker levels, and overall sepsis morbidity and mortality. No difference was detected in pathogen colonization related to the intervention. The probiotic group did exhibit significantly lower interleukin-6 levels at day 15 compared with controls, however clinical outcomes, i.e., sepsis complications and mortality, were unaffected.

Another study investigated the effect of *L. plantarum* 299v on *Clostridioides difficile* colonization in 48 ICU non-colonized patients. Around 19% of control patients had positive rectal swabs for *C. difficile* by ICU discharge compared with zero *C. difficile*-positive patients in the probiotic treatment group. They concluded that probiotic supplementation could reduce *C. difficile* colonization rates in the ICU but that interpretation of these results should be taken with caution given the study’s small sample size and premature termination due to lack of funding. A more recent study investigating the feasibility of a *L. casei* drink found a nonsignificant trend towards lower rates of antibiotic-associated diarrhea and *C. difficile* among ICU patients receiving antibiotics compared with a contemporary control. The efficacy of other probiotic strains for the treatment and prevention of *C. difficile*, including *Saccromyces boulardii*, has been reviewed elsewhere.

Systematic reviews and meta-analyses suggest (with moderate certainty) that probiotics are effective for preventing *C. difficile*-associated diarrhea, though few studies have specifically studied *C. difficile* prevention using probiotics in the ICU. In appropriately selected high-risk populations, probiotics probably do decrease *C. difficile* incidence, but the effect size is likely small and the optimal probiotic is unknown.

Three studies investigated the effects of probiotics primarily containing *L. rhamnosus*. A study conducted in a single ICU randomized 208 adults with a unit stay longer than 48h to either *L. casei rhamnosus* (10⁹ CFU) or placebo via nasogastric tube from day 3 after admission until discharge or death. The primary outcome was time to *Pseudomonas aeruginosa* acquisition as measured in weekly gastric aspirates. Although there was no significant difference in median time before gastric acquisition (16 days in the treatment group versus 30 days in placebo), the probiotic group was found to have a significant delay in respiratory colonization (50 days versus 11 days).

Another study investigated the impact of a probiotic capsule containing primarily *L. rhamnosus* GG, *L. casei*, *L acidophilus*, and *Bifidobacterium bifidum* on mortality, infection, and nasal/gastrointestinal colonization in 167 ICU patients mechanically ventilated for longer than 48h. No significant differences in mortality, colonization, or hospital-acquired infections were found. Catherer-related bloodstream infections were lower in the probiotic group compared with placebo (1.8% of catheter days in the treatment group versus 6.8% control). The authors also conducted a preplanned subgroup analysis of 101 patients who met the criteria for severe sepsis. Severely septic patients treated with probiotics had a threefold reduction in 28-day mortality compared with those in the placebo group. However, an almost equally increased risk for 90-day death was found in non-severely septic patients receiving probiotics. Whether or why the physiology of sepsis might modify the effects of a *Lactobacillus*- and *Bifidobacterium*-containing probiotic is unclear.

A pilot study of 70 ICU patients tested *L. rhamnosus* for prevention of colonization with carbapenem-resistant Enterobacteriaceae (CPE), VRE, extended spectrum β-lactamase producing Enterobacteriaceae (ESBL-E), *Pseudomonas*, or *C. difficile*. Colonization was defined as negative stool or rectal culture results at enrollment with subsequent positive culture results on day 3 and/
or at study exit. No difference was found in the colonization rates between the probiotic and standard of care groups (10% of intervention group versus 15% standard of care), and none of the treatment group patients lost colonization with VRE, *P. aeruginosa*, or *C. difficile* by the specified time points.87

These probiotic studies have some promising results but do not demonstrate a consistent impact on gut pathogen colonization in the ICU. There are also several relevant non-ICU studies that have tested probiotics for the prevention of colonization. A small, single-center, double-blind randomized controlled trial (RCT) was conducted to determine whether *L. rhamnosus GG*-containing yogurt consumption could eradicate VRE carriage in renal ward patients with VRE-positive swabs on admission. All treatment-group patients (*n* = 11) who completed the study had cleared VRE at the 4-week endpoint versus 1 out of 12 in the control group, and 8 out of 11 remained VRE negative at 1 month after study completion. All remaining patients in the control group who had failed to clear VRE at the 4-week time point were then crossed over to receive the probiotic-containing yogurt and had cleared VRE by 8 weeks. Of note, there was a greater antibiotic usage in the probiotic group during the study (10/14 versus 5/13), and 2 patients in the probiotic group received linezolid (to which VRE is susceptible).88

A Swedish randomized trial of 80 patients using a mixture of 8 bacterial strains (primarily *Lactobacillus* and *Bifidobacterium*) found that the probiotic was not superior to placebo at eradication therapy in adult outpatients intestinally colonized with ESBL-E for at least 3 months. There was a nonsignificant trend towards successful decolonization in the probiotic group (13% in probiotic group, 5% in control), with limited power.89 Other non-ICU studies have failed to demonstrate a significant impact of probiotics on gastrointestinal colonization by high resistant organisms. A study of 530 elderly residents in a long-term care facility found no reduction in fecal norfloxacin-resistant *Escherichia coli* in patients treated with the probiotic product *E. coli* strain Nissle 1917 (Mutaflor).90 Similarly, probiotics did not reduce gastrointestinal carriage rates of ampicillin-resistant *Enterococcus faecium* or VRE92 in patients admitted to non-ICU wards with a high prevalence of these resistant organisms.

Like the ICU studies, these outpatient studies have some positive results but do not provide sufficient evidence to support probiotics as an effective method for preventing or eradicating gastrointestinal pathogen colonization. Ultimately the differences in methodology, especially in the composition of the probiotic and the operationalization of colonization, make it hard to draw firm conclusions.

**Synbiotics**

Synbiotics are supplements which contain both probiotic organisms and their prebiotic nutritional substrates as a method to facilitate their survival in the gastrointestinal tract. Such an approach seems logical, but the packaging and drug delivery issues are non-trivial. As a result, many synbiotic RCTs have been sponsored by the synbiotic manufacturer.

Jain *et al.* conducted a 1:1 RCT that compared the incidence and nature of gastric colonization in patients receiving a synbiotic supplement containing *Lactobacillus acidophilus*, *Bifidobacterium lactis*, *Streptococcus thermophiles*, and *L. bulgaricus* with oligofructose to those receiving placebo.93 Patients in the treatment group had significantly fewer gastric aspirates growing multiple strains of bacteria or fungi (9 patients synbiotic versus 18 placebo) as well as a lower incidence of colonization by prespecified potentially pathogenic organisms such as *E. coli* and *Enterococcus faecalis* (10 versus 18, respectively). Synbiotic supplementation was not associated with improved sepsis outcomes although the study was small.93

Salomão *et al.* studied the effect of a synbiotic containing *L. bulgaricus* and *L. rhamnosus* suspended in a fructo-oligosaccharide prebiotic mixture on the eradication of MDR Gram-negative bacilli colonization in adult patients. Although the authors considered a heterogeneous group of patients, 42% of patients in the experimental arm and 32% of patients in the control arm were in an ICU. No significant differences in decolonization were found between the 2 groups (11 placebo versus 8 synbiotic). Systemic antibiotics were used frequently in both groups, which may have influenced both probiotic and pathogenic viability.94
Studies investigating the effects of synbiotics have also been conducted in ICU subpopulations, including liver transplant recipients, trauma patients, patients with acute pancreatitis, and patients undergoing major abdominal surgery. While these studies did not specifically evaluate outcomes related to gastrointestinal colonization, synbiotics were associated with lower incidence of pneumonia, postoperative infections, and sepsis complications during pancreatitis.

Novel approaches to pathogen colonization

Antimicrobial peptides

There are several novel microbiome-based therapies, not yet tested in clinical trials, that deserve mention. An interesting approach involves harnessing the ability of some bacteria to inhibit the growth of closely related organisms through the production of antimicrobial peptides called bacteriocins. Bacteriocins are primarily produced by members of the Firmicutes phylum, including Lactobacillus, Staphylococcus, Acetobacterium, and Streptococcus. These antimicrobials are active against a narrow spectrum of closely related competitors, so they are an attractive, highly specific therapeutic target.

Several animal model studies have investigated the ability of bacteriocins to inhibit colonization of gastrointestinal pathogens. Enterococcus faecalis conjugated with a bacteriocin-expressing plasmid pPD1 effectively outcompetes strains without the plasmid and inhibits growth of multidrug-resistant enterococci. Similar results have been found in the ability of bacteriocin-producing bacteria to inhibit various Streptococcus species, Salmonella enteritidis, Listeria monocytogenes, and Clostridioides difficile.

A related approach was taken by Kim et al. who investigated the effectiveness of a four-strained consortium of commensal bacteria (Clostridium bolteae, Blautia producta, Bacteroides sartorii, and Parabacteroides distasonis) at providing resistance to VRE, a common ICU pathogen, in mice. The strain of B. producta studied, BPScsk, was found to secrete a lantionine-containing bacteriocin, or lantibiotic, that inhibited VRE colonization. The authors demonstrated that abundance of this lantibiotic in patient fecal samples was inversely proportional to the relative abundance of E. faecium. These results suggest that lantibiotics and other bacteriocins can improve colonization resistance, although all the current data come from studies performed in animals. Novel therapies could either selectively promote the growth of bacteriocin-producing bacteria or synthetically reproduce the bacteriocins themselves. The idea of encouraging the growth of benign bacteriocin-producing bacteria has appeal, but a concern is that such organisms might themselves acquire pathogenic traits (e.g. by picking up plasmids containing antibiotic resistance).

Bacteriophage therapy

Bacteriophages are viruses that specifically infect bacteria. Their ability to lyse bacteria at the site of infection can be harnessed as a microbiome-targeted alternative to antibiotics. One proposed advantage of bacteriophage therapy is its specificity for a particular bacterial target, resulting in minimal disruptions to other organisms in the gut microbiome. The efficacy of bacteriophage therapy in targeting gastrointestinal pathogens has been investigated in a limited number of studies. Nale et al. demonstrated that delivery of optimized bacteriophage combinations significantly reduced Clostridioides difficile colonization in vitro and in vivo. Sterile filtrates from donor stool have also been shown to improve symptoms in patients with C. difficile infection (CDI), suggesting that bacteriophages and other nonbacterial components of the microbiome can influence colonization.

Several barriers preclude widespread use of bacteriophage therapy for gastrointestinal pathogen decolonization, including a limited understanding of the cascading effects on other organisms in the microbiome and a lack of safety and efficacy data in humans. There are currently no high-quality data supporting the use of bacteriophage therapy for gastrointestinal pathogen colonization in the ICU.

Competitive inhibition of pathogenic strains

Another interesting decolonization approach harnesses the use of nonpathogenic strains to outcompete their pathogenic counterparts for space and nutrients in the gastrointestinal microbiome. This is best demonstrated in the Clostridioides difficile literature. A phase II RCT conducted in 44...
centers across the USA, Canada, and Europe examined the safety, fecal colonization, recurrence rate, and optimal dosing schedule of non-toxigenic *C. difficile* strain M3 (NTCD-M3) spores for prevention of recurrent CDI. Patients who received NTCD-M3 spores experienced significantly lower rates of CDI recurrence (11% in NTCD-M3 patients *versus* 30% of placebo patients); these rates were even lower in patients who were colonized with NTCD-M3. Although this study demonstrated few safety concerns among patients in the intervention arm, *in vitro* studies have shown that NTCD strains can acquire the toxin A and B pathogenicity locus from toxigenic strains. While this has not been demonstrated *in vivo*, phase III studies are necessary to confirm safety and efficacy.

**Fecal microbiota transplantation**

Fecal microbiota transplantation (FMT) restores gut biodiversity by reintroducing normal gut flora from healthy donors. Among patients with recurrent CDIs, FMT has also been associated with a reduction of antimicrobial resistance genes in stool microbiota. The use of FMT for the treatment of refractory CDI is well established and has been incorporated into guidelines as a treatment option in recurrent CDI.

The success of FMT for CDI led to investigation into its effects on other intestinal pathogens. The thinking is that if FMT, an intervention that comes as close as possible to ‘resetting’ the gut microbiome, does not effectively prevent pathogen colonization, then nothing will. Woodworth et al. recently reviewed 10 FMT studies and case reports with antibiotic-resistant organism decolonization as a primary endpoint and 7 with decolonization as a secondary endpoint. They concluded that while the evidence supports FMT as a method for eradicating colonization by various types of multidrug-resistant bacteria, these studies all have serious limitations including a lack of true controls and long-term safety data. More recently, Huttner et al. randomized 39 adults colonized with extended ESBL-E and/or CPE to either no intervention or a 5-day course of antibiotics followed by FMT. Although the intervention group experienced a slightly lower rate of ESBL-E/CPE colonization, the results did not achieve statistical significance and the conclusions were limited overall by the study’s small sample size.

Only a small handful of cases have been reported detailing the use of FMT among ICU populations. Also, while FMT is reasonably safe, high-profile cases of bacteremia have been reported, in one case leading to death. Currently, the jury is out on FMT in the ICU. Well-designed studies are needed but may be difficult to implement.

**Nutrition in the ICU**

Pre-, pro-, and symbiotic ICU data come from single-center studies usually with <100 patients whereas ICU nutrition trials have been multicenter and powered with thousands of patients. Nutrition trials have not focused on MDRO colonization or the microbiome but rather have investigated the optimal timing, route, and nutrient composition for feeding ICU patients. Early enteral feeding within 24–48h of ICU admission has been the favored approach and is supported by guidelines. This recommendation is based on meta-analyses of smaller studies, and the largest and highest-quality studies have failed to demonstrate a clear clinical difference between early versus late feeding. Though enteral nutrition has been associated with a lower risk of infections compared with parenteral nutrition, benefits in mortality or other clinical outcomes have also not been consistently demonstrated. Finally, optimal caloric intake in critically ill patients has also been a subject of debate. While some studies have shown a mortality benefit among patients with a higher daily calorie intake, others have demonstrated no significant differences in clinical outcomes among patients permissively under-fed or receiving smaller, trophic feeds compared with those receiving full feeding. Implementation of evidenced-based guidelines has been associated with earlier initiation and longer duration of nutrition, however the impact on clinical outcomes has not been consistently demonstrated.

If ICU trials of nutrition have been null or (at best) unconvincing, does that imply pre- or probiotics will be unable to prevent MDRO colonization in the ICU? None of the large ICU nutrition trials were designed to evaluate colonization specifically, so such a conclusion would be premature. The nutrition literature is a cautionary tale for those seeking to develop microbiome-based interventions, but does not mean such interventions are hopeless.
Conclusion
Gastrointestinal colonization by pathogenic, multidrug-resistant bacteria is common among ICU patients and is a precursor to life-threatening infections and multiorgan dysfunction. Microbiome-based therapies offer an attractive alternative to traditional, antibiotic-centric decontamination efforts by enhancing the proliferation of beneficial symbionts and (hopefully) restoring gut microbial equilibrium. The existing evidence for such therapies is encouraging yet quite inconclusive as to whether pre-, pro-, or synbiotics can ameliorate pathogen colonization in the ICU (see summary Table 1). Future studies should state exactly what is being studied, and ideally, why. Such studies must predesignate the outcomes of interest. If MDRO pathogens are the targets, which organisms and precisely how will they be assessed? Is the intervention being tested to eradicate gut colonization that was already present at the time of ICU admission, or to prevent the acquisition of new MDROs during hospitalization? Culture remains the clinical gold standard for diagnosis of almost all important nosocomial pathogens; future studies may want to include culture for predesignated MDROs, as opposed to only sequencing results, as a way of assessing the effectiveness of interventions. To be convincing, studies of microbiome-based interventions will need to be relatively large, blinded, randomized, and appropriately controlled. Microbiome-based interventions have a bright future in the ICU but much work needs to be done before such interventions enter the clinical realm.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.
Conflict of interest statement
The authors declare that there is no conflict of interest.

ORCID ID
Daniel E. Freedberg https://orcid.org/0000-0003-2421-6327

References
1. McDonald D, Ackermann G, Khailova L, et al. Extreme dysbiosis of the microbiome in critical illness. mSphere 2016; 1: e00199-16.
2. Lawson PA, Citron DM, Tyrrell KL, et al. Reclassification of Clostridium difficile as clostridioides difficile (Hall and O’Toole 1935) Prévot 1938. Anaerobe 2016; 40: 95–99.
3. Fay KT, Ford ML and Coopersmith CM. The intestinal microenvironment in sepsis. Biochim Biophys Acta Mol Basis Dis 2017; 1863: 2574–2583.
4. Bouza E and Muñoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008; 32(Suppl. 2): S87–S91.
5. Kondori N, Nowrouzian F, Ajdari M, et al. Candida species as commensal gut colonizers: a study of 133 longitudinally followed Swedish infants. Med Mycol 2020; 58: 485–492.
6. Dickson RP. The microbiome and critical illness. Lancet Respir Med 2016; 4: 59–72.
7. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801–810.
8. Shimizu K, Ogura H, Hamasaki T, et al. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci 2011; 56: 1171–1177.
9. Sandrini S, Aldriwesh M, Alruways M, et al. Microbial endocrinology: host–bacteria communication within the gut microbiome. J Endocrinol 2015; 225: R21–R34.
10. Albenberg L, Espiova TV, Judge CP, et al. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology 2014; 147: 1055–1063.e8.
11. Lu Q, Xu DZ, Sharpe S, et al. The anatomic sites of disruption of the mucus layer directly correlate with areas of trauma/hemorrhagic shock-induced gut injury. J Trauma 2011; 70: 630–635.
12. de Vree JML, Romijn JA, Mok KS, et al. Lack of enteral nutrition during critical illness is associated with profound decrements in biliary lipid concentrations. Am J Clin Nutr 1999; 70: 70–77.
13. Ali M, Naureen H, Tariq MH, et al. Rational use of antibiotics in an intensive care unit: a retrospective study of the impact on clinical outcomes and mortality rate. Infect Drug Resist 2019; 12: 493–499.
14. Jeon MH, Choi SH, Kwak YG, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn Microbiol Infect Dis 2008; 62: 402–406.
15. Papadimitriou-Olivergeris M, Marangos M, Fliou F, et al. Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission. J Antimicrob Chemother 2012; 67: 2976–2981.
16. Vasudevan A, Mukhopadhyay A, Goh EYY, et al. Risk factors for infection/colonization caused by resistant gram negative bacilli in critically ill patients (an observational study of 1633 critically ill patients). Prev Med 2013; 57: S70–S73.
17. Papadimitriou-Olivergeris M, Drougka E, Fliou F, et al. Risk factors for enterococcal infection and colonization by vancomycin-resistant enterococci in critically ill patients. Infection 2014; 42: 1013–1022.
18. Hoang S, Georget A, Asselineau J, et al. Risk factors for colonization and infection by Pseudomonas aeruginosa in patients hospitalized in intensive care units in France. PLoS One 2018; 13: e0193300.
19. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 2016; 352: 535–538.
20. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343: 1925–1932.
21. Almagor J, Temkin E, Benenson I, et al.; DRIVE-AB consortium. The impact of antibiotic use on transmission of resistant bacteria in hospitals: insights from an agent-based model. PLoS One 2018; 13: e0197111.
22. Brown K, Valenta K, Fisman D, et al. Hospital ward antibiotic prescribing and the risks of Clostridium difficile infection. JAMA Intern Med 2015; 175: 626–633.
23. Freedberg DE, Salmasian H, Cohen B, et al. Receipt of antibiotics in hospitalized patients and risk for Clostridium difficile infection in
subsequent patients who occupy the same bed. *JAMA Intern Med* 2016; 176: 1801–1808.

24. Imhann F, Bonder MJ, Vila AV, *et al.* Proton pump inhibitors affect the gut microbiome. *Gut* 2016; 65: 740–748.

25. Eyre DW, Griffiths D, Vaughan A, *et al.* Asymptomatic *Clostridium difficile* colonisation and onward transmission. *PLoS One* 2013; 8: e78445.

26. Bonten M, Gaillard CA, van Tiel FH, *et al.* Continuous enteral feeding counteracts preventive measures for gastric colonization in intensive care unit patients. *Crit Care Med* 1994; 22: 939–944.

27. Song JY, Cheong HJ, Jo YM, *et al.* Vancomycin-resistant enterococcus colonization before admission to the intensive care unit: a clinicopre-demiologic analysis. *Am J Infect Control* 2009; 37: 734–740.

28. Martinez AE, Widmer A, Frei R, *et al.* ESBL-colonization at ICU admission: impact on subsequent infection, carbapenem-consumption, and outcome. *Infect Control Hosp Epidemiol* 2019; 40: 408–413.

29. Ziakas PD, Thapa R, Rice LB, *et al.* Trends and significance of VRE colonization in the ICU: a meta-analysis of published studies. *PLoS One* 2013; 8: e75658.

30. Furuno JP, Perencevich EN, Johnson JA, *et al.* Methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci co-colonization. *Emerg Infect Dis* 2005; 11: 1539–1544.

31. McConville TH, Sullivan SB, Gomez-Simmonds A, *et al.* Carbapenem-resistant enterobacteria colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. *PLoS One* 2017; 12: e0186195.

32. Filius PMG, Gyssens IC, Kershof IM, *et al.* Colonization and resistance dynamics of gram-negative bacteria in patients during and after hospitalization. *Antimicrob Agents Chemother* 2005; 49: 2879–2886.

33. Detsis M, Karanika S and Mylonakis E. ICU acquisition rate, risk factors, and clinical significance of digestive tract colonization with extended-spectrum beta-lactamase–producing enterobacteria: a systematic review and meta-analysis. *Crit Care Med* 2017; 45: 705–714.

34. Tischendorf J, de Avila RA and Safdar N. Risk of infection following colonization with carbapenem-resistant enterobacteria: a systematic review. *Am J Infect Control* 2016; 44: 539–543.

35. Bonten MJ and Weinstein RA. The role of colonization in the pathogenesis of nosocomial infections. *Infection Control Hosp Epidemiol* 1996; 17: 193–200.

36. Vincent JL, Rello J, Marshall J, *et al.; EPIC II Group of Investigators.* International study of the prevalence and outcomes of infection in intensive care units. *JAMA* 2009; 302: 2323–2329.

37. Eggimann P, Garbino J and Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. *Lancet Infect Dis* 2003; 3: 685–702.

38. Altintop YA, Ergul AB, Koc AN, *et al.* Evaluation of Candida colonization and use of the Candida colonization index in a paediatric intensive care unit: a prospective observational study. *Infez Med* 2019; 27: 159–167.

39. Pittet D, Monod M, Suter PM, *et al.* Candida colonization and subsequent infections in critically ill surgical patients. *Ann Surg* 1994; 220: 751–758.

40. Wey SB, Mori M, Pfaller MA, *et al.* Risk factors for hospital-acquired candidemia: a matched case-control study. *Arch Intern Med* 1989; 149: 2349–2353.

41. Eggimann P and Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. *Intensive Care Med* 2014; 40: 1429–1448.

42. Schuster MG, Edwards JE Jr, Sobel JD, *et al.* Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. *Ann Intern Med* 2008; 149: 83–90.

43. DiNubile MJ, Lupinacci RJ, Strohmaier KM, *et al.* Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. *Crit Care* 2007; 22: 237–244.

44. Bassetti M, Giacobbe DR, Vena A, *et al.* Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. *Crit Care* 2019; 23: 219.

45. Falagas ME, Apostolou KE and Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. *Eur J Clin Microbiol Infect Dis* 2006; 25: 419–425.

46. Leroy O, Gangneux JP, Montravers P, *et al.*; AmarCand Study Group. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). *Crit Care Med* 2009; 37: 1612–1618.
47. Agodi A, Barchitta M, Cipresso R, et al. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. *Intensive Care Med* 2007; 33: 1155–1161.

48. Gorrie CL, Mirčeta M, Wick RR, et al. Gastrointestinal carriage is a major reservoir of Klebsiella pneumoniae infection in intensive care patients. *Clin Infect Dis* 2017; 65: 208–215.

49. Freedberg DE, Zhou MJ, Cohen ME, et al. Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection. *Intensive Care Med* 2018; 44: 1203–1211.

50. Stoutenbeek CP, Van Saene HK, Miranda D, et al. A new technique of infection prevention in the intensive care unit by selective decontamination of the digestive tract. *Acta Anaesthesiol Belg* 1983; 34: 209–221.

51. Sánchez-Ramírez C, Hipola-Escalada S, Cabrera-Santana M, et al. Long-term use of selective digestive decontamination in an ICU highly endemic for bacterial resistance. *Crit Care* 2018; 22: 141.

52. de Jonge E, Schultz MJ, Spanjaard L, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. *Lancet* 2003; 362: 1011–1016.

53. De Smet AMGA, Kluytmans JAJW, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. *N Engl J Med* 2009; 360: 20–31.

54. Oostdijk EAN, Kesecioglu J, Schultz MJ, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. *JAMA* 2014; 312: 1429–1437.

55. Wittekamp BH, Plantinga NL, Cooper BS, et al. Decontamination strategies and bloodstream infections with antibiotic-resistant microorganisms in ventilated patients: a randomized clinical trial. *JAMA* 2018; 320: 2087–2098.

56. Oostdijk EAN, de Smet AMGA, Blok HEM, et al. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. *Am J Respir Crit Care Med* 2010; 181: 452–457.

57. Halaby T, Al Naïemi N, Kluytmans J, et al. Emergence of colistin resistance in enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. *Antimicrob Agents Chemother* 2013; 57: 3224–3229.

58. Daneman N, Sarwar S, Fowler RA, et al.; SuDDICU Canadian Study Group. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. *Lancet Infect Dis* 2013; 13: 328–341.

59. Buitinck S, Jansen R, Rijkenberg S, et al. The ecological effects of selective decontamination of the digestive tract (SDD) on antimicrobial resistance: a 21-year longitudinal single-centre study. *Crit Care* 2019; 23: 208.

60. Gibson GR and Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr* 1995; 125: 1401–1412.

61. Wu RY, Määttänen P, Napper S, et al. Non-digestible oligosaccharides directly regulate host kinome to modulate host inflammatory responses without alterations in the gut microbiota. *Microbiome* 2017; 5: 135.

62. Bindels LB, Muñoz RRS, Gomes-Neto JC, et al. Resistant starch can improve insulin sensitivity independently of the gut microbiota. *Microbiome* 2017; 5: 12.

63. Fransen F, Sahasrabudhe NM, Elderman M, et al. β2→1-fructans modulate the immune system in vivo in a microbiota-dependent and-independent fashion. *Front Immunol* 2017; 8: 154.

64. O’Keefe SJD, Ou J, DeLany JP, et al. Effect of fiber supplementation on the microbiota in critically ill patients. *World J Gastrointest Pathophysiol* 2011; 2: 138–145.

65. Fu Y, Moscoso DI, Porter J, et al. Relationship between dietary fiber intake and short-chain fatty acid–producing bacteria during critical illness: a prospective cohort study. *JPEN J Parenter Enteral Nutr* 2020; 44: 463–471.

66. Mathewson ND, Jenq R, Mathew AV, et al. Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. *Nat Immunol* 2016; 17: 505–513.

67. Majid HA, Cole J, Emery PW, et al. Additional oligofructose/inulin does not increase faecal bifidobacteria in critically ill patients receiving enteral nutrition: a randomised controlled trial. *Clin Nutr* 2014; 33: 966–972.

68. Caparrós T, Lopez J and Grau T. Early enteral nutrition in critically III patients with a high-protein diet enriched with arginine, fiber, and antioxidants compared with a standard high-protein diet. The effect on nosocomial infections
Therapeutic Advances in Gastroenterology 13

and outcome. *JPEN J Parenter Enteral Nutr* 2001; 25: 299–309.

69. Karakan T, Ergun M, Dogan I, *et al.* Comparison of early enteral nutrition in severe acute pancreatitis with probiotic fiber supplementation versus standard enteral solution: a prospective randomized double-blind study. *World J Gastroenterol* 2007; 13: 2733–2737.

70. Nikolaou E, Kamilari E, Savkov D, *et al.* Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose. *World J Pediatr* 2019; 16: 168–176.

71. Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, *et al.* Mechanisms of action of probiotics. *Adv Nutr* 2019; 10(Suppl. 1): S49–S66.

72. Mathiya MG and Thantsha MS. Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens. *Gut Pathog* 2017; 9: 28.

73. Manzanares W and Hardy G. The role of prebiotics and symbiotics in critically ill patients. *Curr Opin Clin Nutr Metab Care* 2008; 11: 782–789.

74. Manzanares W, Lemieux M, Langlois PL, *et al.* Probiotic and symbiotic therapy in critical illness: a systematic review and meta-analysis. *Crit Care* 2016; 20: 262.

75. Petrof EO, Dhaliwal R, Manzanares W, *et al.* Probiotics in the critically ill: a systematic review of the randomized trial evidence. *Crit Care Med* 2012; 40: 3290–3302.

76. Barraud D, Bollaert PE and Gibot S. Impact of the administration of probiotics on mortality in critically ill adult patients: a meta-analysis of randomized controlled trials. *Chest* 2013; 143: 646–655.

77. Watkinson PJ, Barber VS, Dark P, *et al.* The use of pre- pro- and symbiotics in adult intensive care unit patients: systematic review. *Clin Nutr* 2007; 26: 182–192.

78. McNaught CE, Woodcock NP, Anderson ADG, *et al.* A prospective randomised trial of probiotics in critically ill patients. *Clin Nutr* 2005; 24: 211–219.

79. Klarin B, Wullt M, Palmquist I, *et al.* Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. *Acta Anaesthesiol Scand* 2008; 52: 1096–1102.

80. Alberda C, Marcushamer S, Hewer T, *et al.* Feasibility of a lactobacillus casei drink in the intensive care unit for prevention of antibiotic associated diarrhea and Clostridium difficile. *Nutrients* 2018; 10: 539.

81. Madoff SE, Urquiaga M, Alonso CD, *et al.* Prevention of recurrent Clostridioides difficile infection: a systematic review of randomized controlled trials. *Anaerobe* Epub ahead of print 4 September 2019. DOI: 10.1016/j. anaerobe.2019.102098.

82. Kalakuntla AS, Nalakonda G, Nalakonda K, *et al.* Probiotics and Clostridium difficile: a review of dysbiosis and the rehabilitation of gut microbiota. *Cureus* 2019; 11: e5063.

83. Tung JM, Dolovich LR and Lee CH. Prevention of Clostridium difficile infection with saccharomyces boulardii: a systematic review. *Can J Gastroenterol Hepatol* 2009; 23: 817–821.

84. Goldenberg JZ, Yap C, Lyvyn L, *et al.* Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. *Cochrane Database Syst Rev* 2017; 12: CD006095.

85. Forestier C, Guelon D, Cluytens V, *et al.* Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients. *Crit Care* 2008; 12: R69.

86. Barraud D, Blard C, Hein F, *et al.* Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. *Intensive Care Med* 2010; 36: 1540–1547.

87. Kwon JH, Bommarito KM, Reske KA, *et al.;* Centers for Disease Control and Prevention (CDC) Prevention Epicenters. Randomized controlled trial to determine the impact of probiotic administration on colonization with multidrug-resistant organisms in critically ill patients. *Infect Control Hosp Epidemiol* 2015; 36: 1451–1454.

88. Manley KJ, Fraenkel MB, Mayall BC, *et al.* Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. *Med J Aust* 2007; 186: 454–457.

89. Ljungquist O, Kampmann C, Resman F, *et al.* Probiotics for intestinal decolonization of ESBL-producing enterobacteriaceae: a randomized, placebo-controlled clinical trial. *Clin Microbiol Infect* 2020; 26: 456–462.

90. Tannock GW, Tiong S, Priest P, *et al.* Testing probiotic strain Escherichia coli Nissle 1917 *(Mutaflor)* for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities. *J Med Microbiol* 2011; 60: 366–370.
91. de Regt MJA, Willems RJL, Hené RJ, et al. Effects of probiotics on acquisition and spread of multiresistant enterococci. *Antimicrob Agents Chemother* 2010; 54: 2801–2805.

92. Vidal M, Forestier C, Charbonnel N, et al. Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. *J Clin Microbiol* 2010; 48: 2595–2598.

93. Jain PK, McNaught CE, Anderson ADG, et al. Influence of synbiotic containing lactobacillus acidophilus La5, bifidobacterium lactis Bb12, streptococcus thermophilus, lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. *Clin Nutr* 2004; 23: 467–475.

94. Salomão MCC, Heluany-Filho MA, Menegueti MG, et al. A randomized clinical trial on the effectiveness of a symbiotic product to decolonize patients harboring multidrug-resistant gram-negative bacilli. *Rev Soc Bras Med Trop* 2016; 49: 559–566.

95. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation – a randomized, double-blind trial. *Am J Transplant* 2003; 5: 125–130.

96. Spindler-Vesel A, Bengmark S, Vovk I, et al. Synbiotics, prebiotics, glutamine, or peptide in early enteral nutrition: a randomized study in trauma patients. *JPEN J Parenter Enteral Nutr* 2007; 31: 119–126.

97. Oláh A, Belágyi T, Pótó L, et al. Symbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. *Hepatogastroenterology* 2007; 54: 590–594.

98. Rayes N, Hansen S, Seehofer D, et al. Early enteral supply of fiber and lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. *Nutrition* 2002; 18: 609–615.

99. Cotter PD, Hill C and Ross RP. Bacteriocins: developing innate immunity for food. *Nat Rev Microbiol* 2005; 3: 777–788.

100. Lopetuso LR, Giorgio ME, Saviano A, et al. Bacteriocins and bacteriophages: therapeutic weapons for gastrointestinal diseases? *Int J Mol Sci* 2019; 20: 183.

101. Kommineni S, Brett DJ, Lam V, et al. Bacteriocin production augments niche competition by enterococci in the mammalian gastrointestinal tract. *Nature* 2015; 526: 719–722.

102. Maricic N, Anderson ES, Opipari AE, et al. Characterization of a multipepptide lantibiotic locus in streptococcus pneumoniae. *mBio* 2016; 7: e01656-15.

103. Klu YAK and Chen J. Influence of probiotics, included in peanut butter, on the fate of selected Salmonella and Listeria strains under simulated gastrointestinal conditions. *J Appl Microbiol* 2016; 120: 1052–1060.

104. Dabour N, Zührer A, Kheadr E, et al. In vivo study on the effectiveness of pediocin PA-1 and pediococcus acidilactici ULS at inhibiting listeria monocytogenes. *Int J Food Microbiol* 2009; 133: 225–233.

105. Rea MC, Sit CS, Clayton E, et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. *Proc Natl Acad Sci U S A* 2010; 107: 9352–9357.

106. Le Lay C, Fernandez B, Hammami R, et al. On lactococcus lactis UL719 competitiveness and nisin (Nisaplin®) capacity to inhibit Clostridium difficile in a model of human colon. *Front Microbiol* 2015; 6: 1020.

107. Le Lay C, Dridi L, Bergeron MG, et al. Nisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination. *J Med Microbiol* 2016; 65: 169–175.

108. Kim SG, Becattini S, Moody TU, et al. Microbiota-derived lantibiotic restores resistance against vancomycin-resistant enterococcus. *Nature* 2019; 572: 665–669.

109. Nale JY, Spencer J, Hargreaves KR, et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. *Antimicrob Agents Chemother* 2016; 60: 968–981.

110. Lin DM, Koskella B and Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. *World J Gastrointest Pharmacol Ther* 2017; 8: 162–173.

111. Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. *Gastroenterology* 2017; 152: 799–811.e7.

112. Hsu BB, Gibson TE, Yeliseyev V, et al. Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model. *Cell Host Microbe* 2019; 25: 803–814.e5.
113. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C difficile infection: a randomized clinical trial. *JAMA* 2015; 313: 1719–1727.

114. Brouwer MSM, Roberts AP, Hussain H, et al. Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. *Nat Commun* 2013; 4: 2601.

115. Bakken JS, Borody T, Brandt LJ, et al.; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. *Clinical Gastroenterol Hepatol* 2011; 9: 1044–1049.

116. Millan B, Park H, Hotte N, et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. *Clin Infect Dis* 2016; 62: 1479–1486.

117. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018; 66: e1–e48.

118. Woodworth MH, Hayden MK, Young VB, et al. The role of fecal microbiota transplantation to reduce intestinal colonization with antibiotic-resistant organisms: the current landscape and future directions. *Open Forum Infect Dis* 2019; 6: ofz288.

119. Huttner BD, de Lastours V, Wassenberg M, et al.; R-Gnosis WP3 study group. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant enterobacteriaceae: a randomized clinical trial. *Clin Microbial Infect* 2019; 25: 830–838.

120. Limketkai BN, Hendler S, Ting Ps, et al. Fecal microbiota transplantation for the critically ill patient. *Nutr Clin Pract* 2019; 34: 73–79.

121. DeFilipp Z, Bloom PP, Soto MT, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. *N Engl J Med* 2019; 381: 2043–2050.

122. McClave SA, Taylor BE, Martindale RG, et al.; Society of Critical Care Medicine, American Society for Parenteral and Enteral Nutrition. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPN). *JPN En* 2016; 40: 159–211.

123. Elke G, van Zanten ARH, Lemieux M, et al. Enteral versus parenteral nutrition in critically ill patients: an updated systematic review and meta-analysis of randomized controlled trials. *Crit Care* 2016; 20: 117.

124. Doig GS, Simpson F, Sweetman EA, et al.; Early PN Investigators of the ANZICS Clinical Trials Group. Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trial. *JAMA* 2013; 309: 2130–2138.

125. Martin CM, Doig GS, Heyland DK, et al.; Southwestern Ontario Critical Care Research Network. Multicentre, cluster-randomized clinical trial of algorithms for critical-care enteral and parenteral therapy (ACCEPT). *CMAJ* 2004; 170: 197–204.

126. Arabi YM, Haddad SH, Aldawood AS, et al. Permissive underfeeding versus target enteral feeding in adult critically ill patients (PermiT trial): a study protocol of a multicenter randomized controlled trial. *Trials* 2012; 13: 191.

127. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Rice TW, Wheeler AP, et al. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. *JAMA* 2012; 307: 795–803.

128. Doig GS, Simpson F, Finfer S, et al.; Nutrition Guidelines Investigators of the ANZICS Clinical Trials Group. Effect of evidence-based feeding guidelines on mortality of critically ill adults: a cluster randomized controlled trial. *JAMA* 2008; 300: 2731–2741.